The discovery of gain-of-function mutations in PIK3CD and PIK3R1 heralded a new era of targeted therapies. These therapies seek to address the underlying cause of APDS by directly suppressing the overactive PI3Kδ pathway, thereby offering more accurate and efficient disease management [23]. Here, PIK3CD is linked to activated PI3K-delta syndrome.